GLP-1s after gastric sleeve: what the evidence actually says
Quick answer
The creator is a post-VSG (vertical sleeve gastrectomy) patient who received a compounded semaglutide prescription from her bariatric surgeon as a cost-reduction strategy, paying $103 total versus an estimated $500 out-of-pocket for brand-name Ozempic. Compounded semaglutide was legally permissible during the FDA-designated shortage period but faces new regulatory restrictions following the FDA's determination in early 2025 that the shortage has ended. Post-bariatric patients using GLP-1 agonists require physician monitoring due to altered drug absorption and overlapping metabolic effects from surgery.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @brickxsthabeauty actually say?
A nurse and gastric sleeve patient shared that her weight loss surgeon prescribed her compounded semaglutide, shipped cold from a Houston compounding pharmacy, for $74 plus $29 shipping. She contrasted this with brand-name Ozempic's out-of-pocket cost of around $500 even with insurance and a coupon. Her conclusion: "What are you doing this paying for the pin?" The implication is clear, compounded semaglutide is a financially smarter choice for people who can't afford brand-name GLP-1 medications.
She also consistently mispronounces the drug as "OZIMPIC" rather than Ozempic, which is a small thing but worth flagging since medication names matter when you're passing health information to 31,000 viewers. The framing is personal testimony, not medical advice, and she credits her surgeon, which is a meaningful distinction from creators who recommend this stuff cold.
Does the science back this up?
The cost comparison is real. The safety picture is more complicated. Compounded semaglutide has legitimate clinical interest behind it, but compounded drugs are not FDA-approved and are not required to meet the same manufacturing standards as brand-name drugs.
Brand-name semaglutide (Ozempic, Wegovy) has an extensive evidence base. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed up to 14.9% body weight reduction at 68 weeks. The SELECT trial (Lincoff et al., 2023, NEJM) demonstrated cardiovascular risk reduction in people with obesity and existing heart disease. These results are tied to the specific formulation, purity, and delivery mechanism studied in those trials. Compounded versions have not been tested in comparable large-scale trials. The FDA issued multiple warnings in 2024 about compounded semaglutide products, citing reports of dosing errors and adverse events, partly because some compounders used semaglutide salt forms rather than the base form used in Ozempic and Wegovy.
What did they get wrong (or right)?
She got the cost math right, and the underlying frustration is completely legitimate. Brand-name GLP-1 medications are priced out of reach for millions of people, and the gap between list price and real out-of-pocket cost is a genuine public health problem.
What she got wrong, or at least skipped over, is the equivalency assumption. Saying compounded semaglutide "makes up Ozempic" is not accurate. Compounded drugs are not the same as their brand-name counterparts in the eyes of the FDA or clinical pharmacology. The active ingredient may be similar, but purity testing, inactive ingredient composition, and sterility standards can vary by compounding pharmacy. The FDA's 2024 guidance specifically warned consumers that compounded semaglutide products may contain different salt forms of the molecule with unknown bioavailability profiles. That is not a minor footnote. It is a clinically relevant difference that her video does not address.
She does credit her surgeon for writing the script, which is the right call. This is not someone telling followers to order peptides off a website. That context matters and she deserves credit for it.
What should you actually know?
Compounded semaglutide became widely available during an FDA-designated shortage of Ozempic and Wegovy. Under federal law, compounding pharmacies are permitted to produce copies of drugs on the shortage list. That shortage was officially resolved by the FDA in early 2025, which legally changes the landscape for compounders. Many pharmacies are no longer permitted to compound semaglutide going forward, which could affect access for people who relied on this route.
If you are post-bariatric surgery, as this creator is, GLP-1 receptor agonists carry specific considerations around absorption, gastric motility, and drug interactions that require physician oversight. This is not a supplement. It is a prescription medication with real metabolic effects, including risks of pancreatitis, thyroid C-cell concerns (based on rodent data), and significant GI side effects. The cost savings are real. The need for medical supervision is equally real.
If cost is the barrier, ask your prescriber about Novo Nordisk's patient assistance programs, and verify any compounding pharmacy through the NABP (National Association of Boards of Pharmacy) before filling a prescription there.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1s after gastric sleeve: what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1s after gastric sleeve: what the evidence actually says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is a post-VSG (vertical sleeve gastrectomy) patient who received a compounded semaglutide prescription from her bariatric surgeon as a cost-reduction strategy, paying $103 total versus an estimated $500 out-of-pocket for brand-name Ozempic.
FormBlends verdict
The creator is a post-VSG (vertical sleeve gastrectomy) patient who received a compounded semaglutide prescription from her bariatric surgeon as a cost-reduction strategy, paying $103 total versus an estimated $500 out-of-pocket for brand-name Ozempic. Compounded semaglutide was legally permissible during the FDA-designated shortage period but faces new regulatory restrictions following the FDA's determination in early 2025 that the shortage has ended. Post-bariatric patients using GLP-1 agonists require physician monitoring due to altered drug absorption and overlapping metabolic effects from surgery.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a post-VSG (vertical sleeve gastrectomy) patient who received a compounded semaglutide prescription from her bariatric surgeon as a cost-reduction strategy, paying $103 total versus an estimated $500 out-of-pocket for brand-name Ozempic. Compounded semaglutide was legally permissible during the FDA-designated shortage period but faces new regulatory restrictions following the FDA's determination in early 2025 that the shortage has ended. Post-bariatric patients using GLP-1 agonists require physician monitoring due to altered drug absorption and overlapping metabolic effects from surgery.
- The FDA formally resolved the semaglutide shortage in early 2025, which restricts most compounding pharmacies from legally producing compounded semaglutide going forward under federal law.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight loss with brand-name semaglutide over 68 weeks. No equivalent trial data exists for compounded versions.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The FDA formally resolved the semaglutide shortage in early 2025, which restricts most compounding pharmacies from legally producing compounded semaglutide going forward under federal law.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight loss with brand-name semaglutide over 68 weeks. No equivalent trial data exists for compounded versions.
- The FDA issued warnings in 2024 that some compounded semaglutide products used salt forms of the molecule, such as semaglutide acetate, which have unknown bioavailability compared to the base form in Ozempic and Wegovy.
- Compounded drugs are not FDA-approved and are not required to meet the same purity, potency, and sterility standards as brand-name drugs, even when the active ingredient is similar.
- Post-bariatric surgery patients face altered drug absorption that requires physician oversight when adding GLP-1 medications. This is not a general-population recommendation.
- Patients seeking cost reduction should verify any compounding pharmacy through the NABP's Verified Pharmacy Program and ask prescribers about Novo Nordisk's patient assistance programs before pursuing compounded alternatives.
- Novo Nordisk's Wegovy savings card has been reported to reduce costs to as low as $0-$25 per month for eligible commercially insured patients, a route worth exploring before compounded options.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Brickxs😘 · TikTok creator
31.3K views on this video
I hope this helps someone in need! #fyp #vsgweightloss #vsgcommunity #gastricsleeve #wls #vsg #bariatriccommunity #blacktiktok #wlsjourney #blackgirlfollowtrain #blacknurses #bariatricsurgeryjourney
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Brickxs😘, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.